FDA Warning Letters Hit Four Peptide Sellers as Compounding Policy Loosens

What Happened

The FDA has sent warning letters to four direct-to-consumer peptide sellers — Peak Performance Peptides, Peptide Partners, NuScience Peptides, and Royal Peptides — accusing each of marketing unapproved new drugs in violation of the Federal Food, Drug, and Cosmetic Act.

All four letters are dated August 24, 2026 and were issued by the Office of Unapproved Drugs and Labeling Compliance within CDER. Each was triggered by a review of the recipient's website conducted in July 2026 — no facility inspection, no product testing, and no adverse event reports were required to open the case.

The enforcement logic was strikingly uniform across all four letters. FDA catalogued claims from product pages, blog posts, and marketing copy that described the products' effects on disease states or bodily functions, treated that website content as product labeling, and concluded the peptides were being marketed with drug-type intended use under Section 201(g)(1) of the FD&C Act — without an approved new drug application under Section 505(a).

Who Is Affected

• Direct-to-consumer peptide sellers whose websites describe therapeutic or physiological effects of the products they ship
• Compounding pharmacies and telehealth platforms, which have absorbed similar letters over compounded GLP-1 marketing throughout 2026
• Consumers and researchers who buy peptides online: none of the compounds named in these letters are under consideration for the 503A bulks list, so FDA treats their therapeutic marketing as plainly unlawful

Timeline

• July 2026 — FDA reviews the four sellers' websites and catalogs their marketing claims
• August 24, 2026 — Warning letters issued to all four companies on the same day
• September 2026 — FDA's Pharmacy Compounding Advisory Committee (PCAC) recommends a number of peptides for the 503A bulks list process, signaling a potentially more permissive compounding pathway
• 2027–2028 (projected) — Formal 503A bulks list inclusion, if it comes, would arrive through notice-and-comment rulemaking that could extend well into this window

What This Means for Researchers

FDA is running two tracks at once, and both matter to anyone in the peptide space.

The agency appears to view expanded access and heightened enforcement as complementary rather than contradictory. Select peptides may become compoundable through legal 503A pathways, while everything marketed outside that framework faces sharper scrutiny. Companies reading the PCAC's signals as implicit permission to sell any peptide face significant legal exposure.

The letters also establish that a website is labeling. Drug-type claims on product pages alone were sufficient to establish intended use and trigger enforcement — no inspection required. Every letter added a paragraph on injectable products, with FDA noting they bypass some of the body's key defenses against toxins and microorganisms.

The practical bottom line: until a peptide is formally placed on the 503A bulks list, FDA considers it an unapproved new drug whenever it is promoted for a therapeutic purpose.

How to Verify Your Peptides

Marketing claims mean nothing without analytical proof. Independent lab testing remains the only way to confirm identity, purity, and contamination status of any research peptide:

• Browse independent peptide testing results for published lab analyses
• Check whether a vendor's products carry verifiable certificates of analysis before ordering

Safe Alternatives

• Use suppliers with documented third-party lab verification — see our vetted vendor directory
• Review peptide research profiles for the evidence base and regulatory standing of individual compounds

Sources

Regulatory announcements; industry legal analysis of federal enforcement actions, September 2026.